Organogenesis Holdings (ORGO) Stock Price, Quote, News & History

Q: What sector and industry does Organogenesis Holdings (ORGO) operate in?

Organogenesis Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Organogenesis Holdings (ORGO) Stock Price, Quote, News & History

ORGONASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$4.01

0.123.08%

At close: Jan 29, 4:00 PM EST

$4.08

0.071.75%

After Hours: 5:43 PM EST

Overview

News Earnings Options Guidance Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$3.91

Close

$4.01

Volume / Avg.

523.88K / 1.81M

Day Range

$3.84 - $4.01

52 Wk Range

2.61 - 7.08

Market Cap

$517.58M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

29.82%

Days to Cover

7.93

Recent Organogenesis Holdings Inc News

Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Avi Kapoor

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Is Organogenesis Stock Trading Lower Friday?

Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-38.79M

Investing Cash Flow (TTM)

-12.86M

Financing Cash Flow (TTM)

21.10M

Free Cash Flow (TTM)

-51.65M

Capital Expenditure (TTM)

-12.86M

Net Change in Cash (TTM)

-30.55M

Analyst Trends and Forecast

1

Aug 25

1

Sep 25

1

Nov 25

2

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$616.83M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.10

PB Ratio (TTM)

1.99

Earnings Yield % (TTM)

-2.00%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.01

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$63.49M

Total Cash

$63.75M

Debt to Equity

0.16

Issuance of Debt (TTM)

-$63.49M

Repayment of Debt (TTM)

-$63.49M

Key Statistics

Open

$3.91

Close

$4.01

Volume / Avg.

523.88K / 1.81M

Day Range

$3.84 - $4.01

52 Wk Range

2.61 - 7.08

Market Cap

$517.58M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

29.82%

Days to Cover

7.93

About

Sector

Health Care

Industry

Biotechnology

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerat...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Organogenesis Holdings (ORGO) stock?

A

You can purchase shares of Organogenesis Holdings (NASDAQ:ORGO) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Organogenesis Holdings (ORGO) competitors?

A

Other companies in Organogenesis Holdings’s space includes: 4D Molecular Therapeutics Inc (NASDAQ:FDMT), Monopar Therapeutics Inc (NASDAQ:MNPR), Altimmune Inc (NASDAQ:ALT), Prothena Corp PLC (NASDAQ:PRTA) and ADC Therapeutics SA (NYSE:ADCT).

Q

What is the forecast, or price target, for Organogenesis Holdings (ORGO) stock?

A

Organogenesis Holdings has a consensus price target of $7.25.

Q

What is the current price for Organogenesis Holdings (ORGO)?

A

The stock price for Organogenesis Holdings (NASDAQ: ORGO) is $4.08 last updated January 29, 2026 at 5:43 PM EST.

Q

Does Organogenesis Holdings (ORGO) pay a dividend?

A

There are no upcoming dividends for Organogenesis Holdings.

Q

When is Organogenesis Holdings (NASDAQ:ORGO) reporting earnings?

A

Organogenesis Holdings does not have any upcoming earnings scheduled.

Q

Is Organogenesis Holdings (ORGO) going to split?

A

There is no upcoming split for Organogenesis Holdings.

Q

What sector and industry does Organogenesis Holdings (ORGO) operate in?

A

Organogenesis Holdings is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

4D Molecular Therapeutics Inc

NASDAQ:FDMT

$8.99

0.22%

Monopar Therapeutics Inc

DiaMedica Therapeutics Inc

NASDAQ:DMAC

$8.31

-1.89%

Kyverna Therapeutics Inc

NASDAQ:KYTX

$8.18

-0.37%

Eupraxia Pharmaceuticals Inc

NASDAQ:EPRX

$8.35

%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$3.91

Close

$4.01

Volume / Avg.

523.88K / 1.81M

Day Range

$3.84 - $4.01

52 Wk Range

2.61 - 7.08

Market Cap

$517.58M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

29.82%

Days to Cover

7.93

Recent Organogenesis Holdings Inc News

Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Avi Kapoor

Why B. Riley Financial Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket

Avi Kapoor

Why Is Organogenesis Stock Trading Lower Friday?

Organogenesis Holdings Inc. (NASDAQ: ORGO) shared topline data on Thursday from the second Phase 3 randomized controlled trial (RCT) of ReNu, a cryopreserved amniotic suspension allograft (ASA) for the management of symptoms associated with

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-38.79M

Investing Cash Flow (TTM)

-12.86M

Financing Cash Flow (TTM)

21.10M

Free Cash Flow (TTM)

-51.65M

Capital Expenditure (TTM)

-12.86M

Net Change in Cash (TTM)

-30.55M

Analyst Trends and Forecast

1

Aug 25

1

Sep 25

1

Nov 25

2

Dec 25

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.1

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$616.83M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

1.10

PB Ratio (TTM)

1.99

Earnings Yield % (TTM)

-2.00%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$2.01

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$63.49M

Total Cash

$63.75M

Debt to Equity

0.16

Issuance of Debt (TTM)

-$63.49M

Repayment of Debt (TTM)

-$63.49M

Key Statistics

Open

$3.91

Close

$4.01

Volume / Avg.

523.88K / 1.81M

Day Range

$3.84 - $4.01

52 Wk Range

2.61 - 7.08

Market Cap

$517.58M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

47

Short Interest

29.82%

Days to Cover

7.93

About

Sector

Health Care

Industry

Biotechnology

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerat...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry